Follow up Approaches in Thyroid Cancer: A Risk Adapted Paradigm

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 2, 2008, Pages 419-435

  Tuttle, R Michael ^a,b   Leboeuf, Rebecca ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN;

CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; FOLLOW UP; HEALTH SURVEY; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THYROID CANCER; THYROIDECTOMY; UNITED STATES;

ALGORITHMS; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; RISK FACTORS; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 43849109780     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.02.008     Document Type: Review

References (20)

1. Ries L.A., Harkins D., Krapcho M., et al. SEER cancer statistics review, 1975-2003, based on November 2005 SEER data submission. Available at:. http://seer.cancer.gov/csr/1975_2003/ Accessed November 1, 2006
2. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26 8 (2002) 879-885
3. Mazzaferri E.L., and Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86 4 (2001) 1447-1463
4. Hundahl S.A., Cady B., Cunningham M.P., et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German thyroid cancer study group. An American college of surgeons commission on cancer patient care evaluation study. Cancer 89 1 (2000) 202-217
5. Ries L.A.G., Melbert D., Krapcho M., et al. SEER cancer statistics review, 1975-2004, national cancer institute. Based on November 2006 SEER data submission, posted to the SEER web site, 2007. Available at:. http://seer.cancer.gov/csr/1975_2004/ Accessed November 23, 2007
6. Bta. British thyroid association and royal college of physicians: guidelines for the management of thyroid cancer in adults. Available at:. www.british-thyroid-association.org Accessed November 1, 2006
7. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 2 (2006) 109-142
8. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 6 (2006) 787-803
9. Sherman S.I. National comprehensive cancer network, clinical practice guidelines in oncology, thyroid cancer V.2.2007. Available at:. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf Accessed November 23, 2007
10. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American association of clinical endocrinologists. American college of endocrinology. Endocr Pract 7 3 (2001) 202-220
11. Watkinson J.C. The British thyroid association guidelines for the management of thyroid cancer in adults. Nucl Med Commun 25 9 (2004) 897-900
12. Tuttle R.M., Leboeuf R., and Martorella A.J. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 36 3 (2007) 753-778
13. Grebe S.K., and Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5 1 (1996) 43-63
14. American Joint Committee on Cancer Staging Manual. 6th edition (2002), Springer-Verlag, New York
15. Dean D.S., and Hay I.D. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7 3 (2000) 229-239
16. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86 9 (2001) 4092-4097
17. Pacini F., Molinaro E., Castagna M.G., et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88 8 (2003) 3668-3673
18. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91 2 (2006) 498-505
19. Wang W., Larson S.M., Tuttle R.M., et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11 12 (2001) 1169-1175
20. Shaha A.R., Shah J.P., and Loree T.R. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 4 4 (1997) 328-333